Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...

Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...

Eli Lilly (NYSE: LLY) stock has had plenty of good ... The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because ...

Warning! GuruFocus has detected 6 Warning Signs with ORCL. As of 2025-02-25, Eli Lilly and Co's intrinsic value as calculated by the Discounted Earnings model is $271.69. It's currently trading at ...

Lilly looks poised to hit a $1 trillion market value Shares of Eli Lilly haven't been doing well in recent months, but over the long run, I think they will more than recover. This is a company ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

The bottom line: We're raising our Lilly fair value estimate to $620 from $580 to account for higher long-term growth from the oncology and immunology portfolio, which supports the firm's wide ...